Regulatory29 May 2026, 07:51 pm
Kabra Drugs: Non-Applicability of Regulation 32 of SEBI (LODR)
AI Summary
Kabra Drugs Ltd. has announced that Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the company for the quarter ended March 31, 2026. This is because the company has not issued any shares through public issue, rights issue, or preferential issue during the specified quarter. Mr. Nanjappan Aravind, Managing Director of Kabra Drugs Limited, has certified the same.
Key Highlights
- Regulation 32 of SEBI (LODR) not applicable to Kabra Drugs for Q4 2026.
- Company did not issue shares via public, rights, or preferential issue.
- Managing Director, Mr. Nanjappan Aravind, certified non-applicability.
Price Impact
More from KABRADG